Statistics from Altmetric.com
Diffuse-type giant cell tumours (GCT), also known as pigmented villonodular synovitis, are characterised by synovial hypertrophy that affects one or several joints, bursas or tendon sheaths, especially in young adults.1 GCT are generally treated by surgical synovectomy.1 ,2 However, the recurrence rate is high, with figures of up to 55%.3 Adjuvant therapies exist, such as external beam radiotherapy (EBM) or intra-articular injection of radiopharmaceuticals (eg, yttrium-90).4–⇓6 Nevertheless, outcomes remain suboptimal and new management options are required. We describe herein the use of bevacizumab, a humanised monoclonal antivascular endothelial growth factor (VEGF) antibody, as an alternative therapy in a case of severe and refractory diffuse-type GCT.
A 24-year-old man without prior past medical history consulted for painful knee swelling. Arthroscopy with biopsy was performed and the …
Contributors MJN and LB were involved in the planning, case identification, conduct and management of the case, the literature review and preparation of the manuscript. AB was involved in the management of the case, the literature review and preparation of the manuscript. JM was involved in the case identification, conduct and management of the case and preparation of the manuscript. CG was involved in the planning, case identification, conduct and management of the case and preparation of the manuscript.
Competing interests None.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.